Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

United Therapeutics Corp

+ Add to Watchlist

UTH:GR

151.967 EUR 0.879 0.58%

As of 13:29:40 ET on 05/05/2015.

Snapshot for United Therapeutics Corp (UTH)

Open: 151.830 Day's Range: 151.202 - 152.736 Volume: 50
Previous Close: 151.088 52wk Range: 62.618 - 178.718 1-Yr Rtn: +103.68%

Stock Chart for UTH

No chart data available.
  • UTH:GR 152.736
  • 1D
  • 1M
  • 1Y
151.088
Interactive UTH Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for UTH

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 14.3236
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) 11.8780
Est. PEG Ratio 1.2639
Market Cap (M EUR) 7,020.70
Shares Outstanding (M) 46.22
30 Day Average Volume 202
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for UTH

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for UTH

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.

Roger A JeffsPresident/Co-CEOShola OyewoleChief Information Officer
David ZaccardelliExecutive VP/COOPaul A MahonExec VP/Secy/General Counsel
More Company Profile & Key Executives for UTH

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil